This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
What's in Store for Edwards Lifesciences (EW) in Q3 Earnings?
by Zacks Equity Research
Within the TAVR arm, Edwards Lifesciences (EW) is likely to have witnessed continued growth in procedures across the United States and worldwide.
Align Technology (ALGN) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
Align Technology's (ALGN) Invisalign First for kids is gaining market share rapidly across all regions.
Humana (HUM) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Humana (HUM) closed at $498.79, marking a -0.24% move from the previous day.
Will Boston Scientific (BSX) Beat Q3 Earnings Estimates?
by Zacks Equity Research
Boston Scientific's (BSX) top line is likely to have improved with non-COVID elective medical procedures running in a full-fledged way in the United States and across the globe.
What's in Store for Thermo Fisher (TMO) in Q3 Earnings?
by Zacks Equity Research
In terms of performance in high-growth and emerging markets, in its flagship facility for cell culture media in Grand Island, NY, Thermo Fisher (TMO) completes capacity expansion.
LabCorp (LH) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
LabCorp's (LH) growth in early development and clinical development are expected to have been offset by central labs on the account of a significant slowdown in COVID-related work.
Quest Diagnostics (DGX) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
The non-COVID base business is expected to have gained from Quest Diagnostics' (DGX) efforts to expand value-based contracts with payers.
UnitedHealth (UNH) Beats on Q3 Earnings, Ups 2022 EPS View
by Zacks Equity Research
UnitedHealth's (UNH) third-quarter results were supported by membership growth and strong Optum performance.
Is Cytokinetics (CYTK) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Cytokinetics (CYTK) and Humana (HUM) have performed compared to their sector so far this year.
Humana (HUM) Brings Affordable MA Plan to U.S. Veterans
by Zacks Equity Research
Humana (HUM) ties up with USAA Life to develop a Medicare Advantage plan that transcends the VA system to fetch added healthcare benefits for veterans.
What's in Store for Abbott Laboratories (ABT) in Q3 Earnings?
by Zacks Equity Research
Going by the industry-wide trend so far, logistical challenges and increasing unit costs might have weighed on the corporate profitability of Abbott (ABT) in Q3.
Walgreens Boots (WBA) Q4 Earnings Top, Operating Loss Concerns
by Zacks Equity Research
The U.S. Healthcare segment of Walgreens Boots (WBA) grows on key contract wins, continued partnership growth and a strong focus on execution.
Cigna (CI) to Offer Low-Cost Health Plans in 11 Texas Counties
by Zacks Equity Research
Cigna (CI) expects the 2023 Open Enrollment Period to start on Nov 1 for Texas residents.
3 Blue-Chip Stocks to Boost Your Portfolio's Defense
by Derek Lewis
The Fed's ongoing tightening cycle, paired with geopolitical uncertainties and lingering COVID-19 restrictions, has caused many stocks to pull back significantly in 2022. However, blue-chip stocks weather a dark fiscal cloud better than most.
Will UnitedHealth Group (UNH) Beat Q3 Earnings Estimates?
by Zacks Equity Research
UnitedHealth Group's (UNH) third-quarter results are likely to benefit from higher premiums and membership growth in its UnitedHealthcare unit, partly offset by elevated technology investment costs.
Are Investors Undervaluing Humana (HUM) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
The Zacks Analyst Blog Highlights NVIDIA, Pfizer, Citigroup, Humana, and Canadian Natural Resources
by Zacks Equity Research
NVIDIA, Pfizer, Citigroup, Humana, and Canadian Natural Resources are included in this Analyst Blog.
Elevance Health's (ELV) Low-Cost MA Plans to Widen U.S. Base
by Zacks Equity Research
Elevance Health (ELV) devises suitable Medicare Advantage plans containing supplemental benefits, which consumers can avail in the 2023 Annual Enrollment Period.
Humana (HUM) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Humana (HUM) closed at $497.04 in the latest trading session, marking a -1.28% move from the prior day.
Top Analyst Reports for NVIDIA, Pfizer & Citigroup
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corporation (NVDA), Pfizer Inc. (PFE) and Citigroup Inc. (C).
Will Humana (HUM) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Humana (HUM) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Zacks Investment Ideas feature highlights: Molina Healthcare, McKesson and Humana
by Zacks Equity Research
Molina Healthcare, McKesson and Humana are part of the Zacks Investment Ideas article.
3 Top-Ranked Healthcare Stocks Thriving in 2022
by Derek Lewis
Healthcare stocks generally carry a defensive nature, helping to shield investors from the market's volatility. Demand for the services these companies provide won't be going anywhere anytime soon.
If You Invested $1000 in Humana a Decade Ago, This is How Much It'd Be Worth Now
by Zacks Equity Research
Holding on to popular or trending stocks for the long-term can make your portfolio a winner.
Humana (HUM) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Humana (HUM) closed the most recent trading day at $503.78, moving +0.85% from the previous trading session.